- Home
- RLYB vs ADGM Comparison
RLYB vs ADGM Comparison
Compare RLYB & ADGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLYB
- ADGM
- Stock Information
- Founded
- RLYB 2018
- ADGM 2011
- Country
- RLYB United States
- ADGM United States
- Employees
- RLYB N/A
- ADGM N/A
- Industry
- RLYB Biotechnology: Pharmaceutical Preparations
- ADGM
- Sector
- RLYB Health Care
- ADGM
- Exchange
- RLYB Nasdaq
- ADGM NYSE
- Market Cap
- RLYB 13.3M
- ADGM 14.7M
- IPO Year
- RLYB 2021
- ADGM N/A
- Fundamental
- Price
- RLYB $0.29
- ADGM $1.46
- Analyst Decision
- RLYB Hold
- ADGM
- Analyst Count
- RLYB 4
- ADGM 0
- Target Price
- RLYB $15.00
- ADGM N/A
- AVG Volume (30 Days)
- RLYB 86.0K
- ADGM 6.1M
- Earning Date
- RLYB 05-08-2025
- ADGM 05-19-2025
- Dividend Yield
- RLYB N/A
- ADGM N/A
- EPS Growth
- RLYB N/A
- ADGM N/A
- EPS
- RLYB N/A
- ADGM N/A
- Revenue
- RLYB $848,000.00
- ADGM $602,000.00
- Revenue This Year
- RLYB N/A
- ADGM N/A
- Revenue Next Year
- RLYB N/A
- ADGM N/A
- P/E Ratio
- RLYB N/A
- ADGM N/A
- Revenue Growth
- RLYB N/A
- ADGM 100.67
- 52 Week Low
- RLYB $0.22
- ADGM $0.63
- 52 Week High
- RLYB $2.00
- ADGM $9.34
- Technical
- Relative Strength Index (RSI)
- RLYB 35.98
- ADGM N/A
- Support Level
- RLYB $0.29
- ADGM N/A
- Resistance Level
- RLYB $0.33
- ADGM N/A
- Average True Range (ATR)
- RLYB 0.02
- ADGM 0.00
- MACD
- RLYB 0.02
- ADGM 0.00
- Stochastic Oscillator
- RLYB 42.19
- ADGM 0.00
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.
About ADGM ADAGIO MEDICAL HOLDINGS INC
Adagio Medical Holdings Inc is an innovator in catheter ablation technologies for treatment of cardiac arrhythmias. The company focuses on developing innovative cryoablation technologies that create contiguous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia.